Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the extension of indication "Xeloda is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen".
The actual benefit of XELODA is substantial.
Clinical Added Value
|no clinical added value||
Given the lack of data showing Xeloda to be superior to 5-fluorouracil, the Committee i considers that Xeloda does not provides IAB versus this comparator.
Évaluation des médicaments